Efectos secundarios y toxicidad de la rifampicina en el tratamiento de la lepra

Terencio de las Aguas, José; Gómez Achevarría, José Ramón; López Pla, Jorge.
Fontilles, Rev. leprol ; 19(3): 259-267, Sep.-Dic. 1993. ilus
Artículo en Español | SES-SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, SES-SP | ID: biblio-1225674

Documentos relacionados

  1. Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts.
  2. The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study).
  3. Single-Dose Rifapentine in Household Contacts of Patients with Leprosy.
  4. Rifapentine in Household Contacts of Patients with Leprosy.
  5. Rifapentine in Household Contacts of Patients with Leprosy. Reply.
  6. The PEP++ study protocol: a cluster-randomised controlled trial on the effectiveness of an enhanced regimen of post-exposure prophylaxis for close contacts of persons affected by leprosy to prevent disease transmission.
  7. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
  8. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options.
  9. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
  10. Implementation approaches for leprosy prevention with single-dose rifampicin: A support tool for decision making.